Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 1/20 | 0.30 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.30 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.30 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.30 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.30 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10005839 | 1.00 | ITPR3 (0.30) | ITPR3ITPR1SSTR1SSTR2SSTR4 | |
| SCHEMBL19608814 | 1.00 | ITPR3 (0.30) | ITPR3ITPR1SSTR1SSTR2SSTR4 | |
| SCHEMBL19768566 | 0.93 | IGF2R (0.35) | — | |
| SCHEMBL1644129 | 0.89 | — | — | |
| SCHEMBL19608817 | 0.89 | — | — | |
| SCHEMBL10005842 | 0.89 | — | — | |
| SCHEMBL10005840 | 0.89 | — | — | |
| SCHEMBL1642430 | 0.89 | — | — | |
| SCHEMBL12674234 | 0.89 | — | — | |
| SCHEMBL19577793 | 0.88 | SSTR1 (0.30) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20230304014-A1 | MIRNA-485 INHIBITOR FOR HUNTINGTON'S DISEASE | BIORCHESTRA CO., LTD. (KR) | 2023-09-28 | — | — | US | disclosed |
| US-11702652-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2023-07-18 | — | — | US | disclosed |
| US-20230126157-A1 | MIRNA-485 INHIBITOR FOR GENE UPREGULATION | BIORCHESTRA CO., LTD. (KR) | 2023-04-27 | — | — | US | disclosed |
| US-20180161356-A1 | TAU ANTISENSE OLIGOMERS AND USES THEREOF | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2018-06-14 | — | — | US | disclosed |
| US-20180112217-A1 | Stereospecific Phosphorothioate LNA | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2018-04-26 | — | — | US | disclosed |
| US-9885035-B2 | Method for the synthesis of a bifunctional complex | NUEVOLUTION A/S (DK) | 2018-02-06 | — | — | US | disclosed |
| US-9879265-B2 | Oligonucleotide conjugates | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2018-01-30 | — | — | US | disclosed |
| US-20170349896-A1 | POLY OLIGOMER COMPOUND WITH BIOCLEAVABLE CONJUGATES | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2017-12-07 | — | — | US | disclosed |
| US-20170335323-A1 | Chiral Library Screen | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2017-11-23 | — | — | US | disclosed |
| US-20090264300-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2009-10-22 | — | — | US | disclosed |
| US-20090239211-A1 | Method For Enrichment Involving Elimination By Mismatch Hybridisation | NUEVOLUTION A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090202573-A1 | POLYMERIC CONJUGATES CONTAINING POSITIVELY-CHARGED MOIETIES | ENZON PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203137-A1 | COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION | SANTARIS PHARMA A/S (DK) | 2009-08-13 | — | — | US | disclosed |
| US-20090181916-A1 | LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR | SANTARIS PHARMA A/S (DK) | 2009-07-16 | — | — | US | disclosed |
| US-20090143232-A1 | METHOD FOR SYNTHESISING TEMPLATED MOLECULES | NUEVOLUTION A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090118213-A1 | RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-B100 EXPRESSION | SANTARIS PHARMA A/S (DK) | 2009-05-07 | — | — | US | disclosed |
| US-7413854-B2 | Method for synthesising templated molecules | NUEVOLUTION A/S (DK) | 2008-08-19 | — | — | US | disclosed |
| US-20080188432-A1 | Short nucleotide subsequences located within number 15; such as locked nucleic acids antisense oligonucleotides; biostability, cell permeability; anticancer agents | SANTARIS PHARMA A/S (DK) | 2008-08-07 | — | — | US | disclosed |
| US-20070026397-A1 | Method for producing second-generation library | NUEVOLUTION A/S (DK) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264300-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | RNGTT, DUT, EMG1 | ITPR3 3088/4885ITPR1 2843/4885SSTR1 4283/4885 |
| US-20090118213-A1 | RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-B100 EXPRESSION | RNASE1, APOB, SERPINB10 | ITPR3 3230/4885ITPR1 2750/4885SSTR1 2115/4885 |
| US-20230126157-A1 | MIRNA-485 INHIBITOR FOR GENE UPREGULATION | NRP1, SORT1, NR4A3 | ITPR3 4409/4885ITPR1 4095/4885SSTR1 1063/4885 |
| US-20180161356-A1 | TAU ANTISENSE OLIGOMERS AND USES THEREOF | MAPT, FUS, TARDBP | ITPR3 2958/4885ITPR1 3626/4885SSTR1 4041/4885 |
| US-20080188432-A1 | Short nucleotide subsequences located within number 15; such as locked nucleic acids antisense oligonucleotides; biostability, cell permeability; anticancer agents | HRAS, KRAS, RNASE1 | ITPR3 2039/4885ITPR1 1955/4885SSTR1 907/4885 |
| US-20090203137-A1 | COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION | CTNNB1, CTNNA1, WNT1 | ITPR3 3597/4885ITPR1 3674/4885SSTR1 4837/4885 |
| US-20230304014-A1 | MIRNA-485 INHIBITOR FOR HUNTINGTON'S DISEASE | HTT, HIPK1, HIPK4 | ITPR3 4464/4885ITPR1 3932/4885SSTR1 3580/4885 |
| US-20090181916-A1 | LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR | AR, ESRRB, ESRRA | ITPR3 3646/4885ITPR1 3812/4885SSTR1 414/4885 |
| US-20090202573-A1 | POLYMERIC CONJUGATES CONTAINING POSITIVELY-CHARGED MOIETIES | PIGO, PHOSPHO1, PAICS | ITPR3 361/4885ITPR1 754/4885SSTR1 2950/4885 |
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | PCSK9, SCD5, PCSK7 | ITPR3 2236/4885ITPR1 2812/4885SSTR1 3863/4885 |
| US-20090143232-A1 | METHOD FOR SYNTHESISING TEMPLATED MOLECULES | FGB, ILK, TBCB | ITPR3 3810/4885ITPR1 4027/4885SSTR1 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.